30 results about "Oral tablets" patented technology

The present invention discloses modified-release bilayer tablets consisting of two layers, layer 1 consisting 500 mg sustained release metformin and layer 2 consisting 250 mg normal release metformin and 5mg / 10mg delayed-release dapagliflozin. This formulation is meticulously designed to regulate blood glucose levels effectively over an extended period. Immediate-release metformin swiftly addresses acute glucose spikes, while sustained-release metformin ensures prolonged glucose control, minimizing fluctuations throughout the day. The delayed-release dapagliflozin component allows for controlled and timed release, managing persistent hyperglycemia synergistically with metformin. By optimizing efficacy and minimizing glucose fluctuations, this innovative formulation offers a promising solution for stable glycemic control in individuals with diabetes. Present invention aims to improve patient outcomes and enhance overall quality of life by maintaining stable glucose levels and reducing the risk of complications associated with uncontrolled diabetes.

This utility model discloses a raw material preparation device for oral tablet processing, relating to the field of tablet processing technology. It includes: a device support frame for mounting and fixing a lifting sleeve mechanism, a flow guiding and output mechanism, and a pushing and stirring mechanism; and a lifting sleeve mechanism comprising an outer sleeve slidably disposed vertically inside an upper flow guide hopper and slidably sleeved on the outside of a rotating disk and a sieve plate. Two sets of synchronously moving lifting components are arranged on both sides of the outer sleeve. Each set of lifting components includes an L-shaped side plate fixedly disposed on the side of the worktable, and an electric push rod is fixedly disposed at the bottom of the L-shaped side plate. This utility model can conveniently output large-particle raw materials and prepared raw materials after screening and preparation, saving manpower while effectively improving preparation efficiency. It also provides a more thorough discharge with less residue.

This disclosure provides crystalline forms of a compound of Formula (A), and pharmaceutical compositions thereof. This disclosure further provides methods for their preparation and use in methods of treatment, prophylaxis, or delay in onset or progression of HIV infection or AIDS in a subject. This disclosure further provides dosage forms, such as oral tablets, of a compound of Formula (A) and its crystalline forms.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are methods for making the tablets comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers, e.g., comprising slugged tablets, wherein the slugged tablets have greater than 90, 91, 92, 93, 94, 95, 96, 97, 98, or 100% of the slugged tablets meet specifications; target width of 10 to 12 mm, or 11 mm; target weight of approximately 475 to 525 mg; and thickness range of approximately 4 to 6 mm, 4.5 to 5.5 mm or 5 mm. Pharmaceutical composition(s) in the form an oral tablet or capsule comprising N-acetylcysteine amide (NACA) for administration of the pharmaceutical composition to a human.

The present invention relates to a pharmaceutical composition comprising ramelteon and a nasal administration formulation. The pharmaceutical composition comprises ramelteon and polyethylene glycol. The pharmaceutical composition of the present invention has high stability and can be used to prepare a pharmaceutical formulation that meets the specifications for nasal administration formulations. Compared with oral tablets, the pharmaceutical composition of the present invention features improved bioavailability of ramelteon and a targeted concentration in brain tissue.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fdlers. Also provided are pharmaceutical composition(s) in the form an oral tablet comprising N-acetylcysteine amide (NACA), wherein the composition has a pharmacokinetic (PK) profile comprising mean plasma concentrations of NACA range from about 200 to 1200 ng / mL after administration of the pharmaceutical composition to a human.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are pharmaceutical composition(s) in the form an oral tablet comprising N-acetylcysteine amide (NACA), wherein the composition has a pharmacokinetic (PK) profile comprising mean plasma concentrations of NACA range from about 200 to 1200 ng / ml after administration of the pharmaceutical composition to a human.

The present disclosure relates to pharmaceutical formulations comprising a HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

The invention related to an oral colon targeted tablet comprising a tablet core coated with a film-coating composition, said tablet core comprising a powder of a therapeutic protein co-dried with a substituted cyclodextrin, and said film-coating coating composition comprising a water-insoluble polymer and a soluble fiber. It also related to a process for making such tablets, and to the use thereof as a medicament.

Provided are oral tablets comprising naproxen sodium, mannitol, a superdisintegrant, and a lubricant. The oral tablets described herein to not comprise a glidant (e.g. colloidal silicon dioxide). These oral tablets may be manufactured using the process of mixing naproxen sodium, mannitol, a superdisintegrant, and magnesium stearate in a continuous in-line mixer to form a tableting mixture; transferring the tableting mixture to a tablet press including three or more compression rollers; and pressing the tableting mixture into naproxen sodium tablets.

The invention relates to an orally administered tablet suitable for active pharmaceutical ingredients comprising a particle population, the particle population comprising a) directly compressible sugar alcohol particles (DC), b) not directly compressible sugar alcohol particles (non-DC) and c) particles comprising a gum base, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in saliva-induced generation upon chewing the tablet, wherein the tablet is designed to be chewed into a coherent residue containing water-insoluble components.

The present disclosure relates to pharmaceutical formulations comprising a HIV capsid inhibitor and methods for the prevention of a human immunodeficiency virus (HIV) infection in a patient.

The invention provides an OAB-14 composition which comprises OAB-14, the particle size d (0.5) of the OAB-14 is 1-2998 nm, and the particle size d (0.9) of the OAB-14 is 2-5532 nm. The OAB-14 is further prepared into various dosage forms such as oral tablets, capsules, pellets, granules, dry suspensions, suspensions and the like. The particle size d (0.5) of the OAB-14 raw material is reduced to be 1-2998 nm, the particle size d (0.9) of the OAB-14 raw material is reduced to be 2-5532 nm, the surfactant is added, the dissolution rate of the raw material is increased, the adhesion of the raw material on the gastrointestinal wall is improved, the bioavailability is increased by 217.91%, the same medicine effect is achieved, and the dosage of the suspension is 40% of that of the raw material medicine.

Pharmaceutical compositions of semaglutide or a salt thereof for intranasal administration for the treatment of diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), or neurodegenerative diseases. The method of delivering semaglutide by the intranasal route avoids repeated injections and improves systemic absorption of semaglutide compared to oral tablets.

The present disclosure relates to pharmaceutical formulations comprising a HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

The invention relates to the technical field of microorganisms, and particularly discloses an acetobacter xylinum HNNB6-Se capable of resisting selenium and producing red selenium-rich nano cellulose, and the preservation number of the acetobacter xylinum HNNB6-Se is GDMCC (China General Microbiological Culture Collection Center) 66552. The strain is obtained by performing sodium selenite gradient stress domestication on an original strain acetobacter xylinum HNNB6, and can grow in a culture medium containing 1-200 [mu] g / mL of sodium selenite and synthesize the red selenium-rich nano bacterial cellulose. The selenium content in the produced nano cellulose (BC) reaches 50-5000 micrograms per gram by dry weight, and the produced nano cellulose (BC) is in stable red (the chromatic value a * is 0.5-25). The red selenium-rich nano bacterial cellulose has a selenium bioaugmentation function, and has outstanding application value in functional food selenium supplements (such as oral tablets and gel foods), medical materials (such as wound dressings) and beauty makeup products.

Described herein are immediate release oral tablet compositions for the treatment of TYK2 mediated diseases. In some embodiments, the TYK2-mediated disease is an autoimmune disease, an inflammatory disease, a proliferative disease, an endocrine disease, a neurological disease, or a disease associated with transplantation.

The present application provides a sublingual tablet composition of lumeritopine tosylate and a preparation method thereof. The sublingual tablet composition of lumeritopine tosylate comprises the following ingredients by weight percentage: lumeritopine tosylate 2% to 15% (1.4 mg / tablet to 10 mg / tablet), filler 15% to 75%, disintegrant 2% to 10%, surfactant 0.1% to 10%, lubricant 0.5% to 2%, glidant 0.5% to 2%, and flavoring agent 0.5% to 2%. The sublingual tablet composition is prepared by direct compression of powder. The sublingual tablet composition has good taste, does not irritate mucosa, is rapidly absorbed under the tongue, and has significantly higher bioavailability than ordinary oral tablets.

The present disclosure provides compositions of agglomerated crystalline salts of medium chain fatty acids having improved properties relative to commercially available salts. These salts are useful as excipients in pharmaceutical oral dosage forms, including as penetration enhancers. The present disclosure provides a sodium caprate crystalline composition having improved powder flowability and compression behavior. The disclosure further provides oral tablets comprising these sodium caprate compositions, including tablets substantially free of any tabletting aid excipients. In various embodiments, these tablets exhibit superior tensile strength and tableting properties than conventional tablets.

The invention provides a nemategravir inhalant and a preparation method and application thereof, and belongs to the technical field of medicines.The nemategravir inhalant comprises nemategravir, water, a surfactant and an auxiliary, has the high lung deposition rate, good stability and low irritation and can overcome the defects of existing nemategravir oral tablets. After the nemategravir inhalant prepared by the embodiment of the invention is inhaled, the residence time of nemategravir in lung tissues can be maintained for more than 12 hours.

The invention related to an oral colon targeted tablet comprising a tablet core coated with a film-coating composition, said tablet core comprising a powder of a therapeutic protein co-dried with a substituted cyclodextrin, and said film-coating coating composition comprising a water-insoluble polymer and a soluble fiber. It also related to a process for making such tablets, and to the use thereof as a medicament.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are pharmaceutical composition(s) in the form an oral tablet comprising N-acetylcysteine amide (NACA), wherein the composition has a pharmacokinetic (PK) profile comprising mean plasma concentrations of NACA range from about 200 to 1200 ng / mL after administration of the pharmaceutical composition to a human.

The invention provides a meloxicam nanocrystal freeze-dried powder pharmaceutical composition. The meloxicam nanocrystal freeze-dried powder pharmaceutical composition comprises meloxicam, a stabilizer and a freeze-drying protective additive, the freeze-drying protective agent comprises one or more of saccharides, salts, polyhydric alcohols, amino acids and polymers. The meloxicam nanocrystal freeze-dried powder pharmaceutical composition disclosed by the invention is prepared by taking meloxicam as an active ingredient and matching with pharmaceutically acceptable auxiliary materials through a specific process. The prepared freeze-dried powder is full in appearance, complete in form, excellent in redissolving performance and good in storage stability, meanwhile, the prepared meloxicam nanocrystal freeze-dried powder can be used as an intermediate preparation, addition of a large number of freeze-drying protective agents in a traditional process can be avoided, and the production cost is reduced. The compound can be further processed and prepared into a plurality of pharmaceutically acceptable transdermal delivery preparations such as gel, plaster and the like. Compared with conventional oral tablets, the transdermal preparation has the advantages of no gastrointestinal tract first-pass effect, reduction of systemic drug exposure, improvement of patient compliance and the like.

The present invention discloses a calcium levofolinate oral tablet for improving children's symptoms of FRAs positive autism spectrum disorder, and relates to the technical field of pharmaceutical preparations, the calcium levofolinate oral tablet comprises: a quick release layer, the quick release layer contains calcium levofolinate, a first disintegrating agent and a first filler; the sustained release-positioning release layer contains calcium levofolinate, a gastrointestinal adhesion material and a pH sensitive polymer, and the pH sensitive polymer is dissolved or swelled in an environment with the pH being greater than or equal to 6.0; the isolating layer is positioned between the quick release layer and the slow release-positioning release layer, and the isolating layer is made of a material which is insoluble in gastric juice but can be quickly dissolved in intestinal juice; the outer layer of the oral tablet is coated with a taste masking film; the technical problems that in the prior art, medicine absorption is unstable, the blood concentration fluctuation is large, a personalized precise administration scheme is lacked, and the medication compliance of child patients is poor are solved.

The invention relates to an oral delivery tablet suitable for active pharmaceutical ingredients comprising a population of particles, the population of particles comprising a) directly compressible (DC) sugar alcohol particles, b) non-directly compressible (non-DC) sugar alcohol particles and c) particles comprising gum base, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in induced saliva generation upon mastication of the tablet, wherein the tablet is designed to be masticated into a coherent residual containing water-insoluble components.

The invention relates to the technical field of Chinese patent medicines, in particular to a tablet for clearing away heart-fire and tranquilizing mind and a preparation method of the tablet for clearing away heart-fire and tranquilizing mind. Cinnabar is a new product within five years, soluble mercury salt is not detected, the cinnabar is stored in a shady, cool and dry place and does not have deterioration phenomena such as moisture absorption and discoloration, and mother-of-pearl and mother-of-pearl are decoction pieces within nearly three years. The traditional Chinese medicine follows the core treatment logic of nourishing yin (tonifying root), clearing heat (treating symptoms) and soothing the nerves (aiming at symptoms), and can be used for soothing the nerves and clearing away heart fire for middle-aged and elderly people, and both symptoms and root causes can be treated; the traditional Chinese medicine is prepared by the processes of cleaning, drying and crushing Chinese herbal medicines, screening with a 100-mesh sieve, sterilizing and the like, and blending and uniformly mixing according to a ratio, can be prepared into oral tablets, is convenient to use and carry, has a definite curative effect, is used for treating long-term insomnia, dreaminess, vexation and palpitation of middle-aged and elderly people, and particularly has a better treatment effect on coronary heart disease and arrhythmia of the middle-aged and elderly people.